On September 16, HENGRUI PHARMA rose 3.01% in regular trading, trading at HKD 45.0/share, with turnover of HKD 39.16 million. The rally was driven by a rapid succession of pipeline catalysts spanning new drug approvals, clinical trial authorizations, and marketing application acceptances.

Most recently, on September 15, the company disclosed that HRS-4139 tablets received clinical trial approval for moderate-to-severe plaque psoriasis, with no competing drug targeting the same mechanism currently approved globally. Cumulative R&D spending on the project stands at approximately RMB 20.4 million. On the same day, ricaxicimab injection was approved to commence a Phase III clinical trial targeting intracranial atherosclerotic stenosis to reduce stroke recurrence risk.

These developments followed a series of significant milestones: ruzaltatug rezetecan was included in the breakthrough therapy designation list for EGFR-mutant non-small cell lung cancer on September 11; SHR-2004 injection for venous thromboembolism prevention had its marketing application accepted on September 14; and oral GLP-1 drug HRS-7535 and atopic dermatitis biologic SHR-1819 both had marketing applications accepted in early September. Additionally, BlackRock raised its H-share stake to 7.17%, signaling institutional confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)